Global Market Size, Forecast, and Trend Highlights Over 2025-2037
Subcutaneous Implantable Defibrillator Market size was valued at USD 9.02 billion in 2024 and is set to exceed USD 15.79 billion by 2037, registering over 4.4% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of subcutaneous implantable defibrillator is evaluated at USD 9.36 billion.
Factors leading to the prevalence of cardiovascular diseases such as increasing geriatric population, unhealthy lifestyle of people, alcohol consumption, smoking, and others, are anticipated to create numerous growth opportunities for the subcutaneous implantable defibrillator market over the coming years.
Subcutaneous Implantable Defibrillator Sector: Growth Drivers and Challenges
Growth Drivers
Increasing Incidence of Cardiovascular Diseases (CVDs) to Propel the Market Growth
According to the WHO, over three quarters of deaths which are caused due to cardiovascular diseases, take place in low and middle-income countries.
CVDs comprise of heart and blood vessels disorders which include coronary heart disease, rheumatic heart disease and others. Heart attacks and strokes contributes about 80% of the CVD deaths, and around one-third of these deaths occur prematurely in people under 70 years of age, according to the WHO. On the back of increasing prevalence of CVDs, there is a significant increase in the demand for subcutaneous implantable defibrillator systems.
Advantages of S-ICD Over Traditional Implantable Cardioverter Defibrillator (ICD) to Drive the Market Growth
The need to minimize the risk caused due to the severe complications associated with transvenous leads, such as infections in the bloodstream, along with the need to remove or replace the leads in the heart, led to the development of the S-ICD systems. S-ICD is somewhat different from a conventional ICD. The wires, also known as leads, which run from the device to the heart, are implanted under the skin in the S-ICD systems, unlike that of the ICD systems, where the leads are implanted in the veins. This procedure allows the leads to be more easily removed and replaced when required. Such advantages associated with S-ICD over conventional ICD is anticipated to create growth opportunities for subcutaneous implantable defibrillator market over the forecast period.
Challenges
High Deployment and Maintenance Cost
Despite the growing market for subcutaneous implantable defibrillator system, the high costs of deploying the device and its maintenance acts as a challenging factor towards the growth of market. Affording such an expensive procedure, especially by the low- and middle-income nations, is anticipated to decrease the demand for subcutaneous implantable defibrillator market over the coming years.
Subcutaneous Implantable Defibrillator Market: Key Insights
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
4.4% |
|
Base Year Market Size (2024) |
USD 9.02 billion |
|
Forecast Year Market Size (2037) |
USD 15.79 billion |
|
Regional Scope |
|
Subcutaneous Implantable Defibrillator Segmentation
The subcutaneous implantable defibrillator market is segmented by end user into hospitals, clinics, cardiac catheterization laboratory, ambulatory surgical centers, and others. Among these segments, the hospitals segment is anticipated to hold the largest market share over the forecast period on the back of severe complications, such as increased heartbeat, shortness of breath, heart palpitations, chest pain, and others, are associated with cardiovascular diseases. According to the World Health Organization (WHO), cardiovascular diseases are the primary cause of death globally, taking an estimate of 17.9 million lives each year. Patients suffering from cardiovascular diseases require critical observation and care. Owing to the availability of such critical care at hospitals, and the increasing preference of individuals for critical care in hospitals, the segment is anticipated to mark remarkable growth during the forecast period.
Our in-depth analysis of the global market includes the following segments:
|
By Product Type |
|
|
By End User |
|
Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.
Customize this ReportSubcutaneous Implantable Defibrillator Industry - Regional Synopsis
Based on regional analysis, the subcutaneous implantable defibrillator market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa region.
North America industry is estimated to dominate majority revenue share by 2037, led by rising geriatric population, and availability of advanced treatment options in the region. Moreover, the initiatives taken by the United States government such as ‘Million Hearts’ to spread awareness against cardiovascular diseases are anticipated to drive the growth of market over the coming years. Million Hearts 2022 is a national initiative of the United States which began in 2017 to prevent 1 million heart attacks and strokes by 2022. On the other hand, the market in Europe is anticipated to follow the subcutaneous implantable defibrillator market in North America on the account of development of advanced technologies and better reimbursement policies in the region.
Companies Dominating the Subcutaneous Implantable Defibrillator Landscape
- Boston Scientific Corporation,
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- LivaNova PLC Company,
- Imricor Medical Systems, Inc.,
- MicroPort Scientific Corporation
- Mayo Clinic US, Medtronic plc
- MRI Interventions, Inc.,
- St. Jude Medical, Inc.,
Boston Scientific Corporation and Medtronic are the leading organizations dealing in subcutaneous implantable defibrillator market. Boston Scientific Corporation, EMBLEM MRI S-ICD, is known for providing protection from sudden cardiac death. This device is also known to mitigate the risks and complications that are associated with the transvenous leads. Moreover, other market players are working towards innovations in market to provide a wide range of products over the coming years.
In the News
- May 2020: Boston Scientific Corporation announced that it has presented the outcomes of the UNTOUCHED study of the EMBLEM S-ICD System at an online series from the Heart Rhythm Society (HRS) known as HRS 2020 SCIENCE.
Author Credits: Radhika Pawar
- Report ID: 718
- Published Date: Dec 23, 2024
- Report Format: PDF, PPT
